Brokerages predict that Maximus, Inc. (NYSE:MMS) will announce $0.77 earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Maximus’ earnings. The highest EPS estimate is $0.79 and the lowest is $0.74. Maximus reported earnings of $0.75 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 2.7%. The firm is scheduled to report its next earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that Maximus will report full-year earnings of $3.05 per share for the current fiscal year, with EPS estimates ranging from $3.03 to $3.07. For the next fiscal year, analysts anticipate that the firm will post earnings of $3.22 per share, with EPS estimates ranging from $3.15 to $3.29. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Maximus.

Maximus (NYSE:MMS) last posted its quarterly earnings data on Thursday, May 4th. The health services provider reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.02. The business had revenue of $622 million during the quarter, compared to the consensus estimate of $620.24 million. Maximus had a return on equity of 26.21% and a net margin of 8.18%. Maximus’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.74 earnings per share.

A number of brokerages have commented on MMS. Zacks Investment Research lowered Maximus from a “hold” rating to a “sell” rating in a report on Tuesday. BidaskClub lowered Maximus from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Canaccord Genuity lowered Maximus from a “buy” rating to a “hold” rating and set a $62.00 target price for the company. in a report on Tuesday, July 4th. KeyCorp reaffirmed a “sector weight” rating on shares of Maximus in a report on Thursday, May 25th. Finally, ValuEngine lowered Maximus from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $61.00.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Maximus, Inc. (NYSE:MMS) to Post $0.77 EPS” was published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/07/19/zacks-brokerages-expect-maximus-inc-nysemms-to-post-0-77-eps.html.

Maximus (NYSE:MMS) traded up 2.73% on Wednesday, hitting $60.61. The company had a trading volume of 405,356 shares. Maximus has a one year low of $43.69 and a one year high of $64.97. The company has a market capitalization of $3.93 billion, a P/E ratio of 19.87 and a beta of 1.40. The stock’s 50-day moving average price is $62.56 and its 200 day moving average price is $60.48.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.045 per share. This represents a $0.18 annualized dividend and a yield of 0.30%. The ex-dividend date of this dividend is Friday, August 11th. Maximus’s dividend payout ratio (DPR) is 5.86%.

In other Maximus news, CEO Richard A. Montoni sold 30,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $62.81, for a total transaction of $1,884,300.00. Following the sale, the chief executive officer now owns 584,114 shares in the company, valued at $36,688,200.34. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Paul R. Lederer sold 8,210 shares of the stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $61.83, for a total value of $507,624.30. Following the sale, the director now owns 51,984 shares in the company, valued at approximately $3,214,170.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 111,346 shares of company stock valued at $6,983,851. 3.10% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Maximus by 22,491.0% in the first quarter. BlackRock Inc. now owns 6,503,511 shares of the health services provider’s stock valued at $404,518,000 after buying an additional 6,474,723 shares in the last quarter. Clearbridge Investments LLC increased its stake in Maximus by 49.5% in the first quarter. Clearbridge Investments LLC now owns 2,004,270 shares of the health services provider’s stock valued at $124,666,000 after buying an additional 663,189 shares in the last quarter. William Blair Investment Management LLC increased its stake in Maximus by 14.7% in the first quarter. William Blair Investment Management LLC now owns 4,416,279 shares of the health services provider’s stock valued at $274,693,000 after buying an additional 566,292 shares in the last quarter. Norges Bank bought a new stake in Maximus during the fourth quarter valued at about $25,597,000. Finally, Columbia Wanger Asset Management LLC increased its stake in Maximus by 115.7% in the first quarter. Columbia Wanger Asset Management LLC now owns 787,691 shares of the health services provider’s stock valued at $48,994,000 after buying an additional 422,499 shares in the last quarter. Hedge funds and other institutional investors own 98.03% of the company’s stock.

About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on Maximus (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.